GlassScriptPhysician profile
Juan A Silva
NPI 1790738110
$12,841.27
in general payments reported to CMS, 2019-2025
40 companies · $1,413 in 2025
The $1,413 reported for 2025 was more than what 91% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,480 · 2020: $1,542 · 2021: $1,452 · 2022: $3,953 · 2023: $1,452 · 2024: $1,548 · 2025: $1,413.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,372 · Education: $41.52.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,371.73 |
| Education | $41.52 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $4,756.43 | 2019-2025 | Vraylar, Linzess, Ubrelvy |
| Boehringer Ingelheim Pharmaceuticals, INC. | $880.22 | 2019-2025 | Jardiance, Synjardy |
| Corcept Therapeutics | $865.34 | 2019-2025 | Korlym |
| Novo Nordisk INC | $849.98 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Lilly USA, LLC | $652.95 | 2019-2025 | Mounjaro, Zepbound, Jardiance |
| Pfizer INC. | $561.97 | 2019-2025 | |
| Abbott Laboratories | $555.11 | 2021-2025 | Freestyle Libre 3, Freestyle Libre 2 |
| Merck Sharp & Dohme LLC | $501.97 | 2019-2025 | Verquvo, Capvaxive, Vaxneuvance |
| Janssen Pharmaceuticals, INC | $461.37 | 2019-2021 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $408.51 | 2019-2025 | Xifaxan |
| Astrazeneca Pharmaceuticals LP | $368.97 | 2019-2024 | Farxiga |
| Boston Scientific Corporation | $156.37 | 2025 | Watchman Flx |
| Xeris Pharmaceuticals, INC. | $139.65 | 2023-2025 | Gvoke Hypopen |
| Sanofi Pasteur INC. | $139.23 | 2019-2024 | |
| Sanofi-Aventis U.S. LLC | $130.06 | 2019-2020 |
Show all 40 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $111.44 | 2019-2023 | |
| Amgen INC. | $109.39 | 2019-2025 | Krystexxa |
| Medtronic Vascular, INC. | $100.00 | 2019 | |
| Amarin Pharma, INC. | $95.50 | 2020-2021 | |
| Horizon Therapeutics Plc | $95.45 | 2022-2023 | Krystexxa |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $90.99 | 2024-2025 | Caplyta |
| Exact Sciences Corporation | $82.15 | 2024-2025 | Cologuard Collection Kit, The Cologuard Plus Collection Kit |
| Radius Health, INC. | $81.16 | 2020-2021 | |
| Glaxosmithkline, LLC. | $76.79 | 2023-2025 | Shingrix, Arexvy, Trelegy Ellipta |
| Bayer Healthcare Pharmaceuticals INC. | $75.46 | 2024-2025 | |
| Otsuka America Pharmaceutical, INC. | $65.92 | 2024-2025 | Rexulti |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $50.99 | 2021 | |
| Gilead Sciences, INC. | $48.42 | 2019-2021 | |
| Arbor Pharmaceuticals, INC. | $48.00 | 2019-2020 | |
| Phathom Pharmaceuticals, INC. | $47.14 | 2024-2025 | Voquezna |
| Medtronic, INC. | $42.98 | 2021 | |
| Phadia US INC. | $31.14 | 2021 | |
| Zealand Pharma US, INC. | $29.89 | 2021-2022 | |
| E.R. Squibb & Sons, L.L.C. | $29.54 | 2020 | |
| Lundbeck LLC | $21.74 | 2024 | Rexulti |
| Idorsia Pharmaceuticals US INC | $21.16 | 2023 | Quviviq |
| Alk-Abello, INC | $19.60 | 2025 | Grastek, Odactra, Ragwitek |
| Hikma Pharmaceuticals USA | $13.96 | 2021 | |
| Cequr Corporation | $12.99 | 2025 | Cequr Simplicity |
| Breathe Technologies, INC. | $11.34 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Juan Silva listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.